Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China
· Delayed Price · Currency is CNY 8.60
+0.37 (4.50%)
May 30, 2025, 3:04 PM CST
Xiangxue Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,691 | 1,839 | 2,273 | 2,166 | 2,930 | 2,923 | Upgrade
|
| Other Revenue | 19.76 | 19.76 | 26.76 | 20.75 | 40.87 | 148.61 | Upgrade
|
| Revenue | 1,711 | 1,859 | 2,299 | 2,187 | 2,971 | 3,072 | Upgrade
|
| Revenue Growth (YoY) | -24.95% | -19.16% | 5.13% | -26.38% | -3.30% | 10.26% | Upgrade
|
| Cost of Revenue | 1,384 | 1,451 | 1,556 | 1,654 | 2,229 | 2,093 | Upgrade
|
| Gross Profit | 327.25 | 407.61 | 743.33 | 533.38 | 741.4 | 979.12 | Upgrade
|
| Selling, General & Admin | 484.13 | 522.29 | 583.02 | 602.22 | 659.02 | 583.58 | Upgrade
|
| Research & Development | 78.04 | 79.39 | 89.76 | 94.79 | 90.6 | 66.99 | Upgrade
|
| Other Operating Expenses | 6.32 | 7.08 | 12.83 | 10.44 | 13.6 | 10.5 | Upgrade
|
| Operating Expenses | 601.93 | 641.53 | 693.66 | 708.73 | 763.79 | 667.27 | Upgrade
|
| Operating Income | -274.68 | -233.92 | 49.67 | -175.35 | -22.39 | 311.85 | Upgrade
|
| Interest Expense | -235.62 | -232.85 | -237.06 | -213.2 | -202.06 | -130.29 | Upgrade
|
| Interest & Investment Income | 2.98 | 2.78 | 1.2 | 51.24 | 41.84 | 34.78 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | -0 | 0.08 | 0.01 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.02 | -0.71 | -70.83 | -23.79 | -8.94 | -7.27 | Upgrade
|
| EBT Excluding Unusual Items | -497.31 | -464.71 | -257.01 | -361.02 | -191.54 | 209.07 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -353.87 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.36 | -5.36 | -60.01 | -0.01 | 15.64 | -9.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | 8.06 | 6.99 | 0.09 | 4.97 | 2.34 | -3.57 | Upgrade
|
| Asset Writedown | -344.17 | -334.92 | -105.38 | -129.64 | -90.7 | -1.27 | Upgrade
|
| Legal Settlements | - | - | - | - | -16.58 | -52.84 | Upgrade
|
| Other Unusual Items | -56.65 | -44.07 | 33.37 | -26.16 | -1.07 | 23.8 | Upgrade
|
| Pretax Income | -894.43 | -842.07 | -388.95 | -511.86 | -635.78 | 166.14 | Upgrade
|
| Income Tax Expense | 18.23 | 19.15 | 12.8 | -7.22 | 22.92 | 24.34 | Upgrade
|
| Earnings From Continuing Operations | -912.67 | -861.22 | -401.75 | -504.65 | -658.7 | 141.8 | Upgrade
|
| Minority Interest in Earnings | 2.03 | 2.66 | 12.78 | -25.41 | -29.77 | -43.38 | Upgrade
|
| Net Income | -910.63 | -858.56 | -388.96 | -530.06 | -688.47 | 98.42 | Upgrade
|
| Net Income to Common | -910.63 | -858.56 | -388.96 | -530.06 | -688.47 | 98.42 | Upgrade
|
| Net Income Growth | - | - | - | - | - | 28.63% | Upgrade
|
| Shares Outstanding (Basic) | 651 | 660 | 659 | 663 | 662 | 656 | Upgrade
|
| Shares Outstanding (Diluted) | 651 | 660 | 659 | 663 | 662 | 656 | Upgrade
|
| Shares Change (YoY) | -10.12% | 0.18% | -0.50% | 0.09% | 0.89% | 2.90% | Upgrade
|
| EPS (Basic) | -1.40 | -1.30 | -0.59 | -0.80 | -1.04 | 0.15 | Upgrade
|
| EPS (Diluted) | -1.40 | -1.30 | -0.59 | -0.80 | -1.04 | 0.15 | Upgrade
|
| EPS Growth | - | - | - | - | - | 25.00% | Upgrade
|
| Free Cash Flow | -112.92 | -17.07 | 207.41 | -139.89 | -305.18 | -498.83 | Upgrade
|
| Free Cash Flow Per Share | -0.17 | -0.03 | 0.32 | -0.21 | -0.46 | -0.76 | Upgrade
|
| Gross Margin | 19.13% | 21.93% | 32.33% | 24.39% | 24.96% | 31.87% | Upgrade
|
| Operating Margin | -16.06% | -12.58% | 2.16% | -8.02% | -0.75% | 10.15% | Upgrade
|
| Profit Margin | -53.23% | -46.19% | -16.92% | -24.24% | -23.18% | 3.20% | Upgrade
|
| Free Cash Flow Margin | -6.60% | -0.92% | 9.02% | -6.40% | -10.27% | -16.24% | Upgrade
|
| EBITDA | -60.04 | -15.7 | 282.2 | 60.29 | 125.02 | 447.17 | Upgrade
|
| EBITDA Margin | -3.51% | -0.84% | 12.27% | 2.76% | 4.21% | 14.56% | Upgrade
|
| D&A For EBITDA | 214.64 | 218.22 | 232.53 | 235.64 | 147.41 | 135.32 | Upgrade
|
| EBIT | -274.68 | -233.92 | 49.67 | -175.35 | -22.39 | 311.85 | Upgrade
|
| EBIT Margin | -16.06% | -12.58% | 2.16% | -8.02% | -0.75% | 10.15% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 14.65% | Upgrade
|
| Revenue as Reported | 1,711 | 1,859 | 2,299 | 2,187 | 2,971 | 3,072 | Upgrade
|
| Advertising Expenses | - | 7.78 | 6.33 | 9.46 | 34.1 | 20.55 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.